School of Pharmacy

Explore this Section

• Undergraduate
• Postgraduate
• Medicines Management
  • Research Agenda
  • Publications
  • MTRAC
  • Keele Medicines Management Services
    • About Us
    • West Midlands Prescribing Advisory Service
    • Events
    • Swap Shop
    • Open Access Materials
    • Feedback
    • Useful Links
    • Disclaimers
  • National Pathology Benchmarking Service
  • Prescribing Decision Support
  • ESCA Toolkit
• NPC Plus
• Virtual Patient
• Staff & Research Interests
• Contact Us
• IT Support

• Faculty of Health > 
• School of Pharmacy > 
• Medicines Management > 
• Keele Medicines Management Services > 
• About Us

Prescribing Information to Support QIPP document available

A new Prescribing Information to Support QIPP report is now available.  West Midlands users should log-in to access their individual report, alternatively an anonymous open-access version is available.

Last year's report was accepted by NICE as a 'shared learning' example, supporting implementation of NICE guidance and an example copy of the report can be viewed on the NICE website.

Introduction to the report

The report includes a breakdown of key therapeutic topics recognised by the National Prescribing Centre (NPC; now the NICE Medicines and Prescribing Centre) as having significant potential for making a contribution to the challenged posed by QIPP. The medicines and products selected have been identified from the NPC document “Key therapeutic topics- medicines Management options for local implementation”, published in July 2011 and updated in April 2012.

This report presents data from a number of different sources, including:

• Primary care prescribing (ePACT) data
• QOF prevalence data
• Admissions data
• Hospital prescribing data
• Outpatient referral data

By including these data, our intention is to give medicines management leads, prescribers and commissioners as complete a picture of activity as possible, to identify the opportunities to improve standards and provide safer care as well improving efficiency and effectiveness.

Foreword

I am pleased to have been asked to draft this foreword to the annual QIPP report from the team at Keele University, the content of which is a valuable contribution to both the QIPP medicines strategy and to the wider medicines optimisation agenda.  Data included in this report present an opportunity for commissioners and providers to engage in discussion around better medicines use to deliver improved and safer care, whilst at the same time achieving efficiencies and effectiveness.

Medicines optimisation is a key component in delivering QIPP and this is recognised by the NHS Commissioning Board. Delivery will always be local and as such this report will be extremely helpful in delivering improved outcomes and better medicines use.

Of particular note are the opportunities afforded by the wide range of therapy areas in this report and linkages to patient activity. We are going through a period of unprecedented financial challenge in the NHS, coupled with major transformational change. This report offers you and others in the NHS a helpful tool to focus attention around optimising medicines use.

Congratulations and thank you to the authors at Keele University for this valuable publication. I would encourage all recipients and readers of the report to engage in utilising the content to patient and NHS benefit.

Clare Howard

National QIPP Lead for Medicines Use and Procurement, Department of Health

Feedback on the report is welcome and should be sent to medman@keele.ac.uk